ANI Pharmaceuticals Reports Record Q3 2025 Earnings, Raises Guidance

ANI Pharmaceuticals reported record Q3 2025 financial results, with net revenues of $227.8 million, up 53.6% YoY, and adjusted non-GAAP EBITDA of $59.6 million, up 69.8% YoY. Purified Cortrophin Gel net revenues reached $101.9 million, a 93.8% increase YoY. The company raised its 2025 guidance, expecting total net revenue to be between $854.0 million and $873.0 million, and adjusted non-GAAP EBITDA to be between $221.0 million and $228.0 million. Rare Disease net revenues are expected to represent approximately 50% of total company net revenues in 2025.